pl-88, page-12

Thanks for that. I find the investor side very useful as I mainly concentrate on the science.

Is always very difficult to quantify chance of success in such a clinical trial and I take onboard the confidence of medigen to take trial on. The 160mg efficacy data was reasonable - 13% absolute risk reduction is a good result - gives a number needed to treat of 7.7 (so need to treat only 7.7 people for 50 weeks to reduce one recurrence - very acceptable number). Just wish 250mg was as good/better. I had also noticed the low volume rise which made me a touch nervous.

Thanks for the ACL pointer - have been watching for 8 months or so but not holding. Will look into it in more depth tomorrow perhaps. Cheers.